PROCEPT BioRobotics (NASDAQ:PRCT) Announces Quarterly Earnings Results

PROCEPT BioRobotics (NASDAQ:PRCT) posted its quarterly earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.07), FiscalAI reports. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The company had revenue of $98.29 million during the quarter, compared to the consensus estimate of $100.52 million.

Here are the key takeaways from PROCEPT BioRobotics’ conference call:

• PROCEPT reported third-quarter revenue of $98.3 million, up 18% year over year, with U.S. procedures rising 22% and U.S. handpiece and consumable revenue increasing 21%. Handpiece pricing remained strong, and the company said field inventory had normalized.
• Procedure growth remains challenged by weaker utilization on legacy AquaBeam systems as surgeons shift cases to HYDROS; HYDROS accounts performed more than 35% more procedures than legacy accounts. Management expects about 54,000 procedures for 2026, within its guidance range, but reaching that level implies the strongest sequential procedure growth of the year in Q4.
• The company placed 62 HYDROS systems, including 20 replacements, at an average U.S. selling price of about $495,000. Although greenfield placements fell short of expectations in Q3 due largely to timing, management maintained that it expects to meet or exceed its initial full-year system targets and said capital demand remains healthy.
• The net loss widened to $26.5 million from $21.4 million a year earlier, and adjusted EBITDA loss increased to $9.8 million from $7.4 million as operating expenses rose with investment. Management expects positive adjusted EBITDA in Q4 and described approximately 20% revenue growth in 2027 as a planning baseline, while noting that formal guidance will come later.

PROCEPT BioRobotics Stock Up 7.4%

PRCT traded up $1.49 during mid-day trading on Wednesday, reaching $21.66. 2,828,443 shares of the stock were exchanged, compared to its average volume of 1,502,198. PROCEPT BioRobotics has a 1 year low of $16.67 and a 1 year high of $38.11. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. The stock has a market capitalization of $1.24 billion, a PE ratio of -11.16 and a beta of 0.88. The company has a 50 day moving average price of $19.33 and a two-hundred day moving average price of $23.27.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, CEO Larry Wood purchased 23,900 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were acquired at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the acquisition, the chief executive officer owned 23,900 shares in the company, valued at $498,315. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 1,043 shares of company stock worth $21,851 over the last 90 days. 4.00% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PRCT. Robert W. Baird set a $20.00 target price on PROCEPT BioRobotics in a research note on Wednesday, August 5th. Oppenheimer reiterated a “market perform” rating on shares of PROCEPT BioRobotics in a report on Wednesday, September 9th. Piper Sandler upgraded PROCEPT BioRobotics to a “strong-buy” rating in a report on Friday, October 16th. Wells Fargo & Company lowered PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 target price on the stock. in a research report on Wednesday, August 5th. Finally, William Blair lowered shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Three research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.50.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.